The decrease in PPARα targets in both long-term HFD-fed Fsp27−/− mice (23) and ASO-treated mice (herein) suggest that a combination of ASO plus a PPARα synthetic agonist might be necessary to stimulate the efficient mobilization and oxidation of hepatic lipids, and to provide therapeutic reduction of hepatic steatosis. This evidence concerns the gene PPARA and Hepatic steatosis.